ALLO logo

ALLO
Allogene Therapeutics Inc

3,678
Mkt Cap
$765.25M
Volume
5.53M
52W High
$4.46
52W Low
$0.8621
PE Ratio
-2.66
ALLO Fundamentals
Price
$2.31
Prev Close
$2.35
Open
$2.33
50D MA
$2.39
Beta
1.63
Avg. Volume
5.46M
EPS (Annual)
-$0.8652
P/B
1.81
Rev/Employee
$0.00
$135.30
Loading...
Loading...
News
all
press releases
Annie Yoshiyama Sells 9,586 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Annie Yoshiyama sold 9,586 shares of the business's stock in a transaction on Tuesday, April 21st. The shares were sold at an average...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Allogene Therapeutics (NASDAQ:ALLO) SVP Annie Yoshiyama Sells 9,586 Shares
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Annie Yoshiyama sold 9,586 shares of the company's stock in a transaction dated Tuesday, April 21st. The stock was sold at an average...
MarketBeat·3d ago
News Placeholder
Allogene Therapeutics (NASDAQ:ALLO) Shares Down 6% - Should You Sell?
Allogene Therapeutics (NASDAQ:ALLO) Trading Down 6% - What's Next...
MarketBeat·5d ago
News Placeholder
HC Wainwright Issues Optimistic Estimate for ALLO Earnings
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Analysts at HC Wainwright boosted their Q2 2026 EPS estimates for Allogene Therapeutics in a report released on Thursday, April 16th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.15) per share for th...
MarketBeat·7d ago
News Placeholder
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) has received an average rating of "Moderate Buy" from the fifteen research firms that are presently covering the company, Marketbeat...
MarketBeat·9d ago
News Placeholder
Allogene Therapeutics (NASDAQ:ALLO) Trading Up 13.1% Following Analyst Upgrade
Allogene Therapeutics (NASDAQ:ALLO) Trading 13.1% Higher After Analyst Upgrade...
MarketBeat·10d ago
News Placeholder
Allogene Therapeutics (NASDAQ:ALLO) Upgraded to "Neutral" at JPMorgan Chase & Co.
JPMorgan Chase & Co. raised Allogene Therapeutics from an "underweight" rating to a "neutral" rating in a research report on Thursday...
MarketBeat·11d ago
News Placeholder
Allogene Therapeutics (NASDAQ:ALLO) Shares Gap Down - Time to Sell?
Allogene Therapeutics (NASDAQ:ALLO) Shares Gap Down - Should You Sell...
MarketBeat·11d ago
News Placeholder
Traders Buy Large Volume of Put Options on Allogene Therapeutics (NASDAQ:ALLO)
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock investors purchased 4,437 put options on the company. This is an...
MarketBeat·11d ago
News Placeholder
Allogene Therapeutics (NASDAQ:ALLO) Upgraded to Strong-Buy at Jefferies Financial Group
Jefferies Financial Group raised Allogene Therapeutics to a "strong-buy" rating in a research note on Monday...
MarketBeat·12d ago
<
1
2
...
>

Latest ALLO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.